Shares of Johnson & Johnson
JNJ,
+0.24%
fell 2.4% early Tuesday, to pace the Dow Jones Industrial Average’s
DJIA,
-0.16%
premarket decliners, after health regulators put a pause on the company’s COVID-19 vaccine following “extremely rare” cases of blood clots. The stock’s implied price decline would shave about 25 points off the Dow’s price, while Dow futures
YM00,
-0.21%
shed 96 points, or 0.3%. Currently 21 of the Dow’s 30 components are declining ahead of the open. J&J’s stock has edged up 2.7% year to date through Monday, while the Dow has climbed 10.3%.
